LY-2510924

N/A

Report date: 2024/07/16 20:00:09
NME

Base Information

Drug NameLY-2510924
Drug Alias NameAnti-CXCR4 peptide - Eli LillyT-134LY-2510924
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionC-X-C motif chemokine receptor 4 antagonists
TargetsC-X-C motif chemokine receptor 4
Therapy Area/IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Renal Cell +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And CompanyThe University Of Texas MD Anderson Cancer Center
Active IndicationsN/A
Inactive IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Renal Cell +[4] 

Other Information

ATC CodeN/A
Related LinksN/A